Holen Sie sich die Stockscreener-App
6.62
2.16%
0.14
Handel nachbörslich:
6.62
Schlusskurs vom Vortag:
$6.48
Offen:
$6.52
24-Stunden-Volumen:
142.61K
Relative Volume:
0.66
Marktkapitalisierung:
$356.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.77M
KGV:
-9.4802
EPS:
-0.6983
Netto-Cashflow:
$-29.56M
1W Leistung:
-0.30%
1M Leistung:
-14.14%
6M Leistung:
-4.47%
1J Leistung:
+89.14%
1-Tages-Spanne:
$6.5026
$6.86
1-Wochen-Bereich:
$6.10
$7.4699
52-Wochen-Spanne:
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.62 | 349.16M | 0 | -32.77M | -29.56M | -0.6983 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-30 | Eingeleitet | TD Cowen | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst - MarketBeat
What is HC Wainwright’s Forecast for DMAC FY2029 Earnings? - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Issues Pessimistic Estimate for DMAC Earnings - MarketBeat
Top Wall Street forecasters revamp DiaMedica Therapeutics expectations ahead of Q4 earnings - MSN
[ARS] DiaMedica Therapeutics Inc. SEC Filing - Stock Titan
Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares - Stock Titan
H.C. Wainwright reiterates DiaMedica stock rating on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates DiaMedica stock rating on trial progress - investing.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2025 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update - The Globe and Mail
DMAC Should I Buy - Intellectia AI
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
DiaMedica Therapeutics Inc.Common Stock - FinancialContent
DiaMedica Therapeutics Reports 2025 Financial Results - National Today
DiaMedica reiterates plan for ReMEDy2 interim analysis in 2H 2026 as stroke trial approaches 70% of 200 patients - MSN
DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost - investing.com
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - BioSpace
Loss Report: Is DiaMedica Therapeutics Inc a cyclical or defensive stockTrade Analysis Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Strengthens Financial Position and Advances Clinical Programs - gurufocus.com
Rising R&D widens loss as DiaMedica (NASDAQ: DMAC) funds DM199 - Stock Titan
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results, Meets Expectations - MarketBeat
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
DM199 pipeline: DiaMedica Therapeutics (NASDAQ: DMAC) targets stroke and preeclampsia - Stock Titan
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Price Action: Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday - Defense World
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - weeklyvoice.com
User - The Chronicle-Journal
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
Market Review: How does DiaMedica Therapeutics Inc compare to its peers2026 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? - MSN
DiaMedica receives Health Canada clearance for preeclampsia study - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now? - msn.com
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday - MarketBeat
Geopolitics Watch: Is DiaMedica Therapeutics Inc. stock attractive for ETFsQuarterly Profit Review & Daily Profit Focused Screening - Naître et grandir
DiaMedica Therapeutics raises capital via share offering - MSN
DiaMedica Therapeutics, Inc. $DMAC Shares Purchased by Paragon Associates & Paragon Associates II Joint Venture - MarketBeat
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Diamedica Therapeutics (DMAC) and Veeva Systems (VEEV) - The Globe and Mail
DiaMedica receives Health Canada clearance for preeclampsia study By Investing.com - Investing.com South Africa
Sentiment Watch: Whats the fair value of AEV CL stockAnalyst Downgrade & Low Risk Investment Opportunities - baoquankhu1.vn
DiaMedica (DMAC) Gains Health Canada Approval for Preeclampsia T - GuruFocus
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - The AI Journal
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Diamedica Therapeutics Inc-Aktie (DMAC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
| STAHLBERG JAN | 10% Owner |
Aug 25 '25 |
Buy |
6.00 |
338,265 |
2,029,252 |
7,654,045 |
| STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
| STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):